Scientific Program – Details

<div style="border:1px solid black;">

SESSION 1

Tumor Characterization:
Discovery Leading to Diagnostic Development

Thursday 27 October 2011 (Afternoon)

</div>

Chairs: Maria Grazia Daidone (EU) & Tracy Lively (US)

TOPIC 1 (13h30 – 15h30)

WHAT CAN WE LEARN FROM LARGE-SCALE GENOMIC DATA?

TCGA-Success Story in Ovarian Cancer
(P. Spellman)

International Cancer Genome Consortium: A Promising Story in Pancreatic Cancer
(A. Scarpa)

Debate on Strategies for Data Release: Rapid Public Release vs. Controlled Access:
Access to Clinical Trials Data - the NSABP Experience
The METABRIC (Molecular Taxonomy of Breast Cancer Consortium) project -
Generating a large genomics dataset
(C. Caldas & L. Wickerham)

miRNA and Lung Cancer: Early Detection in High-Risk Subjects
(G. Sozzi)

TOPIC 2 (16h00 – 18h00)

HOW DO WE HANDLE LARGE-SCALE GENOMIC DATA?

Driving Discovery Through Data Integration and Analysis
(J. Quackenbush)

Meta-Analysis of Genomic Datasets for Robust Signature Discovery and Disease Characterization
(L. Wessels)

**Debate on Access to Tissue Specimens from Clinical Trials: When is the Preliminary Data Strong
Enough to Invest Highly Annotated Samples?**
(I. Lubensky & J. Hall)

Selected abstract for oral presentation (abs. #24):
Somatic allelic selection in the tumor as an indicator of cancer relevance: insights from statistical mining
of the Cancer Genome Atlas data
(T. LaFramboise)

Selected abstract for oral presentation (abs. #29):
Development of a genomic-clinical classifier model for predicting clinical recurrence in patients with
localized prostate cancer
(E. Davicioni)

<u>Scientific Program – Details (Cont'd)</u>

SESSION 2

Novel Strategies for Biomarker Design and Development

Friday 28 October 2011 (Morning)

<u>Chairs</u>: Nadia Harbeck (EU) & Barbara Conley (US)

TOPIC 3 (08h00 – 10h00)

DEVELOPMENT OF OMICS BASED ASSAYS FOR CLINICAL USE

microRNAs as Prognostic and Predictive Markers in Breast Cancer
(J. Martens)

Potential Clinical Applications of Whole Genome Profiling
(A. Prat)

Omics-based tests: What is the Evidence and How to present it
(J. Bogaerts)

Requirements for Prospective Use of Omics-based tests in NCI-Sponsored Trials
(L. McShane)

Selected abstract for oral presentation (abs. #54):
A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical
outcome in two independent cohorts
(*W. Barry*)

TOPIC 4 (10h30 – 12h30)

MOLECULAR IMAGING BIOMARKERS

Functional Activity Versus Clinical Predictivity
(L. Shankar)

Promising Imaging Techniques for Prognosis and Prediction in Cancer
(S. Stroobants)

Integration of Metabolic Imaging (PET CT) into Clinical Trials
(W. Weber)

Translating Molecular Imaging Agents into Phase 3 Trials
(P. Jacobs)

Selected abstract for oral presentation (abs. #93):
The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and
folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients
(*S. Ghamande*)

Scientific Program – Details (Cont'd)

SESSION 3

Relevant Molecular Pathways in Cancer Cells

Friday 28 October 2011 (Afternoon)

Chairs: Jean-Yves Blay (EU) & Magdalena Thurin (US)

TOPIC 5 (13h30 – 15h30)

BIOMARKER FOR ONCOGENIC PATHWAYS: AGENTS IN EARLY DEVELOPMENT

Adapting Treatment in Metastatic and Adjuvant Phases to the Nature of Mutation:
The Example of GIST
(M. Debiec-Rychter)

IDH1/IDH2 Mutations Predict Survival in Glioma and AML
(M. Hegi)

MDM2 inhibitors to reactivate p53 in Human Cancer
(L. Vassilev)

Cancer Stem Cells
(W. Matsui)

Selected abstract for oral presentation (abs. #16):
Identification of JAK2/STAT3 as a novel therapeutic target in Kras mutant colorectal cancer models
(*M. Kalimutho*)

TOPIC 6 (16h00 – 18h00)

BIOMARKER FOR ONCOGENIC PATHWAYS: AGENTS IN LATE DEVELOPMENT

FLT3 is a Stratification Factor for Targeted Therapy Treatments in Adult and Pediatric
AML-Phase III Trials
(S. Meshinchi)

Predictive and Pharmacodynamic Markers of Susceptibility for Targeting IGF-1R Receptor
(F. Hirsch)

Various Molecular Forms of ALK Predict Sensitivity to Targeted Therapy in Hematological
and Solid Tumors
(M. Wasik)

Predictive and Pharmacodynamic Markers of PI3K pathway Inhibitors:
Focus on PI3K, AKT and mTOR inhibitors
(J. Tabernero)

Selected abstract for oral presentation (abs. #75):
An unbiased shRNA based lentiviral screen identifies tyrosine kinases that are important for survival
and radioresistance in Head and Neck Squamous Cell Carcinoma
(*E-J. Van Limbergen*)

Scientific Program – Details (Cont'd)

SESSION 4

Advances in Overcoming Drug Resistance

Saturday 29 October 2011 (Morning)

<u>Chairs</u>: Dean Fennell (EU) & Francisco Esteva (US)

TOPIC 7 (08h00 – 10h00)

NOVEL INSIGHTS INTO MOLECULAR MECHANISMS OF RESISTANCE

Using Genomic Landscapes to Map Biomarkers of Drug Sensitivity
(U. McDermott)

Cancer Genomics-based Mouse Models to Identify Novel Mechanisms of Drug Resistance
(R. DePinho)

Epigenetics and Drug Resistance
(S. Sharma)

Synthetic Lethal Approaches and Biomarker Discovery Related to Radiation Sensitization
in Prostate Cancer
(R. Bristow)

Selected abstract for oral presentation (abs. #85):
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic
antibody cetuximab
(K. Yonesaka)

TOPIC 8 (10h30 – 12h30)

CLINICAL IMPLICATIONS OF DRUG RESISTANCE BIOMARKERS

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
(T. Lion)

Overcoming Drug Resistance in Melanoma
(J. Sosman)

Biomarkers for Targeted Therapy Selection in Non-Small Cell Lung Cancer
(L. Paz-Ares)

KRAS Mutations in Colorectal Cancer (CRC): Lessons Learned and Future Progress
(G. Eckhardt)

Selected abstract for oral presentation (abs. #50):
Initial experience with the EANM accreditation procedure of FDG PET/CT devices
(R. Boellaard)